Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Clinical trial NCT05126277 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05126277
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-14
- Primary completion
- 2027-09-21
- Enrollment
- 452
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.